Xenon Pharmaceuticals Inc. (XENE) — Financial statements
Income statement, balance sheet, and cash flow for Xenon Pharmaceuticals Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 8 | 0.00 | 0.00↓100.0% | 9↓48.8% | 18 | |
| Cost of Revenue | 3↓0.7% | 3↓98.5% | 168 | 0.00 | 0.00 | |
| Gross Profit | 5↑293.6% | -3↑98.5% | -168↓1875.6% | 9↓48.8% | 18 | |
| Operating Expenses | ||||||
| R&D Expenses | 301↑43.0% | 210↑25.6% | 168↑58.4% | 106↑40.2% | 75 | |
| General & Administrative Expenses | 80↑15.6% | 69↑48.0% | 47↑41.9% | 33↑49.4% | 22 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 80↑15.6% | 69↑48.0% | 47↑41.9% | 33↑49.4% | 22 | |
| Other Expenses | -3↑0.7% | -3↑98.5% | -168 | 0.00 | 0.00 | |
| Operating Expenses | 378↑36.6% | 277↑494.6% | 47↓66.4% | 139↑42.2% | 97 | |
| Total Costs & Expenses | 381↑36.3% | 279↑30.5% | 214↑54.5% | 139↑42.2% | 97 | |
| Operating Results | ||||||
| Operating Income | -373↓33.6% | -279↓30.5% | -214↓65.7% | -129↓63.5% | -79 | |
| Depreciation & Amortization | 3↓0.7% | 3↓27.7% | 4↑152.0% | 1↑55.1% | 0.91 | |
| EBITDA | -342↓45.2% | -236↓12.0% | -211↓64.8% | -128↓63.6% | -78 | |
| EBIT | -345↓44.7% | -238↓11.4% | -214↓65.7% | -129↓63.5% | -79 | |
| Interest & Other Income | ||||||
| Net Interest Income | 27↓36.0% | 42↑51.9% | 28↑217.0% | 9↑1769.7% | 0.47 | |
| Interest Income | 27↓36.0% | 42↑51.9% | 28↑217.0% | 9↑1769.7% | 0.47 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | -28↑31.1% | -41 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 28↓31.1% | 41↑30.3% | 31↑706.8% | 4↑3602.9% | 0.11 | |
| Income Before Tax | -345↓44.7% | -238↓30.5% | -183↓45.9% | -125↓58.8% | -79 | |
| Income Tax Expense | 1↑124.8% | -4↓1300.3% | -0.29↓347.5% | 0.12↑2066.7% | -0.01 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -346↓47.6% | -234↓28.5% | -182↓45.5% | -125↓58.9% | -79 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -346↓47.6% | -234↓28.5% | -182↓45.5% | -125↓58.9% | -79 | |
| Bottom-Line Net Income | -346↓47.6% | -234↓28.5% | -182↓46.0% | -125↓62.1% | -77 | |
| EPS (Basic) | -4.36↓44.9% | -3.01↓10.3% | -2.73↓32.5% | -2.06↓16.4% | -1.77 | |
| EPS (Diluted) | -4.36↓44.9% | -3.01↓10.3% | -2.73↓32.5% | -2.06↓16.4% | -1.77 | |
| Weighted Average Shares | 79↑1.7% | 78↑16.5% | 67↑10.5% | 61↑38.8% | 44 | |
| Weighted Average Diluted Shares | 79↑1.7% | 78↑16.5% | 67↑10.5% | 61↑38.8% | 44 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.